MedDataX Logo

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

NCT ID: NCT00036127

Last Updated: 2013-11-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2002-04-30

Study Completion Date

2003-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to learn if the alternate formulation is effective in agitated schizophrenic patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

agitated schizophrenic patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aripiprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Agitated schizophrenic patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Local Institution

Anaheim, California, United States

Site Status

Local Institution

Cerritos, California, United States

Site Status

Local Institution

Chula Vista, California, United States

Site Status

Local Institution

Rosemead, California, United States

Site Status

Local Institution

San Diego, California, United States

Site Status

Local Institution

Atlanta, Georgia, United States

Site Status

Local Institution

Macon, Georgia, United States

Site Status

Local Instituton

Hoffman Estates, Illinois, United States

Site Status

Local Institution

Las Vegas, Nevada, United States

Site Status

Local Institution

Nashua, New Hampshire, United States

Site Status

Local Institution

New York, New York, United States

Site Status

Local Institution

Beachwood, Ohio, United States

Site Status

Local Institution

Philadelphia, Pennsylvania, United States

Site Status

Local Institution

Charleston, South Carolina, United States

Site Status

Local Institution

Houston, Texas, United States

Site Status

Local Institution

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007 Jan;68(1):111-9. doi: 10.4088/jcp.v68n0115.

Reference Type DERIVED
PMID: 17284138 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CN138-050

Identifier Type: -

Identifier Source: org_study_id